Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway

References

• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–14. doi:10.1126/science.aar4060.
   PubMed Web of Science ®Google Scholar
• Gajewski TF. The Next Hurdle in Cancer Immunotherapy: overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin. Oncol. 2015;42(4):663–671. doi:10.1053/j.seminoncol.2015.05.011.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017;168(4):707–723. doi:10.1016/j.cell.2017.01.017.
   PubMed Web of Science ®Google Scholar
• Lau J, Cheung J, Navarro A, Lianoglou S, Haley B, Totpal K, Sanders L, Koeppen H, Caplazi P, McBridee J, et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nat. Commun 2017;8:14572. doi:10.1038/ncomms14572.
   Web of Science ®Google Scholar
• Jung J, Kim HY, Kim D-G, Park SY, Ko AR, Han J-Y, Kim HT, Lee JS, Lee Y. Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis. Cancer Res. Treat. 2021;53(1):77–86. doi:10.4143/crt.2020.543.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 2013;14(10):1014–1022. doi:10.1038/ni.2703.
   PubMed Web of Science ®Google Scholar
• Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp. Mol. Med. 2020;52(9):1475–1485. doi:10.1038/s12276-020-00500-y.
   PubMed Web of Science ®Google Scholar
• Lee YS, Lee WS, Kim CW, Lee SJ, Yang H, Kong SJ, Ning J, Yang KM, Kang B, Kim WR, et al. Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer. J. Immunother. Cancer. 2020;8(2):e000857. doi:10.1136/jitc-2020-000857.
   PubMed Web of Science ®Google Scholar
• Qian F, Villella J, Wallace PK, Mhawech-Fauceglia P, Tario JD Jr., Andrews C, Matsuzaki J, Valmori D, Ayyoub M, Frederick PJ, et al. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Res. 2009;69(13):5498–5504. doi:10.1158/0008-5472.
   PubMed Web of Science ®Google Scholar
• Koblish HK, Hansbury MJ, Bowman KJ, Yang G, Neilan CL, Haley PJ, Burn TC, Waeltz P, Sparks RB, Yue EW, et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol. Cancer Ther. 2010;9(2):489–498. doi:10.1158/1535-7163.MCT-09-0628.
   PubMed Web of Science ®Google Scholar
• Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T, Wolchok JD. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Rep. 2015;13(2):412–424. doi:10.1016/j.celrep.2015.08.077.
   PubMed Web of Science ®Google Scholar
• Li F, Zhao Y, Wei L, Li S, Liu J. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer. Cancer Biol. Ther. 2018;19(8):695–705. doi:10.1080/15384047.2018.1450116.
   PubMed Web of Science ®Google Scholar
• Litzenburger UM, Opitz CA, Sahm F, Rauschenbach KJ, Trump S, Winter M, Ott M, Ochs K, Lutz C, Liu X, et al. Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget. 2014;5(4):1038–1051. doi:10.18632/oncotarget.1637.
   PubMedGoogle Scholar
• Wei L, Zhu S, Li M, Li F, Wei F, Liu J, Ren X. High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer. Front. Immunol 2018:9:724. doi:10.3389/fimmu.2018.00724.
   Web of Science ®Google Scholar
• Li Y, Tredget EE, Ghaffari A, Lin X, Kilani RT, Ghahary A. Local expression of indoleamine 2,3-dioxygenase protects engraftment of xenogeneic skin substitute. J. Invest. Dermatol. 2006;126(1):128–136. doi:10.1038/sj.jid.5700022.
   PubMed Web of Science ®Google Scholar
• Nonaka H, Saga Y, Fujiwara H, Akimoto H, Yamada A, Kagawa S, Takei Y, Machida S, Takikawa O, Suzuki M. Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killercell function and angiogenesis promotion. Int. J. Oncol. 2011;38(1):113–120. doi:10.3892/ijo_00000830.
   PubMed Web of Science ®Google Scholar
• Klar R, Michel S, Schell M, Hinterwimmer L, Zippelius A, Jaschinski F. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression. Cancer Immunol. Immunother. 2020;69(1):57–67. doi:10.1007/s00262-019-02438-1.
   PubMed Web of Science ®Google Scholar
• Bishnupuri KS, Alvarado DM, Khouri AN, Shabsovich M, Chen B, Dieckgraefe BK, Ciorba MA. IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis. Cancer Res. 2019;79(6):1138–1150. doi:10.1158/0008-5472.CAN-18-0668.
   PubMed Web of Science ®Google Scholar
• Labadie BW, Bao R, Luke JJ. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis. Clin. Cancer Res. 2019;25(5):1462–1471. doi:10.1158/1078-0432.CCR-18-2882.
   PubMed Web of Science ®Google Scholar
• Liu Q, Hua S, Wang X, Chen F, Gou S. The introduction of immunosuppressor (TDO inhibitor) significantly improved the efficacy of irinotecan in treating hepatocellular carcinoma. Cancer Immunol. Immunother. 2021;70(2):497–508. doi:10.1007/s00262-020-02697-3.
   PubMed Web of Science ®Google Scholar
• Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 2000;164(7):3596–3599. doi:10.4049/jimmunol.164.7.3596.
   PubMed Web of Science ®Google Scholar
• Riess C, Schneider B, Kehnscherper H, Gesche J, Irmscher N, Shokraie F, Classen CF, Wirthgen E, Domanska G, Zimpfer A, et al. Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib. Front. Immunol. 2020;11:55. eCollection 2020. doi:10.3389/fimmu.2020.00055.
   PubMed Web of Science ®Google Scholar
• Bekki S, Hashimoto S, Yamasaki K, Komori A, Abiru S, Nagaoka S, Saeki A, Suehiro T, Kugiyama Y, Beppu A, et al. Serum kynurenine levels are a novel biomarker to predict the prognosis of patients with hepatocellular carcinoma. PLoS One. 2020;15(10):e0241002. doi:10.1371/journal.pone.0241002.
   PubMed Web of Science ®Google Scholar
• Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011;478(7368):197–203. doi:10.1038/nature10491.
   PubMed Web of Science ®Google Scholar
• Li H, Ning S, Ghandi M, Kryukov GV, Gopal S, Deik A, Souza A, Pierce K, Keskula P, Hernandez D, et al. The landscape of cancer cell line metabolism. Nat. Med. 2019;25(5):850–860. doi:10.1038/s41591-019-0404-8.
   PubMed Web of Science ®Google Scholar
• Ferns DM, Kema IP, Buist MR, Nijman HW, Kenter GG, Jordanova ES. Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival. Oncoimmunology. 2015;4(2):e981457. doi:10.4161/2162402X.2014.981457.
   PubMed Web of Science ®Google Scholar
• Botticelli A, Cerbelli B, Lionetto L, Zizzari I, Salati M, Pisano A, Federica M, Simmaco M, Nuti M, Marchetti P. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? J. Transl. Med. 2018;16(1):219. doi:10.1186/s12967-018-1595-3.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liang X, Dong W, Fang Y, Lv J, Zhang T, Fiskesund R, Xie J, Liu J, Yin X, et al. Tumor-Repopulating Cells Induce PD-1 Expression in CD8(+) T Cells by Transferring Kynurenine and AhR Activation. Cancer Cell. 2018;33(3):480–94 e7. doi:10.1016/j.ccell.2018.02.005.
   PubMed Web of Science ®Google Scholar
• Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, Cheng Y, Kim JW, Qiao J, Zhang L, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin. Cancer Res. 2014;20(20):5290–5301. doi:10.1158/1078-0432.CCR-14-0514.
   PubMed Web of Science ®Google Scholar
• Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J. Immunother. Cancer 2014:2:3. doi:10.1186/2051-1426-2-3.
   Google Scholar
• Yue EW, Sparks R, Polam P, Modi D, Douty B, Wayland B, Glass B, Takvorian A, Glenn J, Zhu W, et al. INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology. ACS Med. Chem. Lett. 2017;8(5):486–491. doi:10.1021/acsmedchemlett.6b00391.
   PubMed Web of Science ®Google Scholar
• Campesato LF, Budhu S, Tchaicha J, Weng CH, Gigoux M, Cohen IJ, Redmond D, Mangarin L, Pourpe S, Liu C, et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nat. Commun. 2020;11(1):4011. doi:10.1038/s41467-020-17750-z.
   PubMed Web of Science ®Google Scholar
• Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, Leffet L, Hansbury MJ, Thomas B, Rupar M, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010;115(17):3520–3530. doi:10.1182/blood-2009-09-246124.
   PubMed Web of Science ®Google Scholar
• Mullard A. IDO takes a blow. Nat. Rev. Drug Discov. 2018;17(5):307. doi:10.1038/nrd.2018.67.
   Web of Science ®Google Scholar
• Muller AJ, Manfredi MG, Zakharia Y, Prendergast GC. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. Semin. Immunopathol. 2019;41(1):41–48. doi:10.1007/s00281-018-0702-0.
   PubMed Web of Science ®Google Scholar
• Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019;20(8):1083–1097. doi:10.1016/S1470-2045(19)30274-8.
   PubMed Web of Science ®Google Scholar
• Puccetti P, Fallarino F, Italiano A, Soubeyran I, MacGrogan G, Debled M, Velasco V, Bodet D, Eimer S, Veldhoen M, et al. Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers. PLoS One. 2015;10(4):e0122046. doi:10.1371/journal.pone.0122046.
   PubMed Web of Science ®Google Scholar
• Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frederick R, De Plaen E, Uyttenhove C, Wouters J, Masereel B, et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc. Natl. Acad. Sci. U. S. A. 2012;109(7):2497–2502. doi:10.1073/pnas.1113873109.
   PubMed Web of Science ®Google Scholar
• Yang H, Lee WS, Kong SJ, Kim CG, Kim JH, Chang SK, Kim S, Kim G, Chon HJ, Kim C. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J. Clin. Invest. 2019;129(10):4350–4364. doi:10.1172/JCI125413.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461. doi:10.1016/j.ccell.2015.03.001.
   PubMed Web of Science ®Google Scholar
• Chon HJ, Lee WS, Yang H, Kong SJ, Lee NK, Moon ES, Choi J, Han EC, Kim JH, Ahn JB, et al. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade. Clin. Cancer Res. 2019;25(5):1612–1623. doi:10.1158/1078-0432.CCR-18-1932.
   PubMed Web of Science ®Google Scholar
• Kim CG, Kim C, Yoon SE, Kim KH, Choi SJ, Kang B, Kim HR, Park S-H, Shin E-C, Kim -Y-Y, et al. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. J. Hepatol. 2021;74(2):350–359. doi:10.1016/j.jhep.2020.08.010.
   PubMed Web of Science ®Google Scholar
• Chon HJ, Kim H, Noh JH, Yang H, Lee WS, Kong SJ, Lee SJ, Lee YS, Kim WR, Kim JH, et al. STING signaling is a potential immunotherapeutic target in colorectal cancer. J. Cancer. 2019;10(20):4932–4938. doi:10.7150/jca.32806.
   PubMed Web of Science ®Google Scholar
• Oh C-M, Chon HJ, Kim C. Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors. Int. J. Mol. Sci. 2020;21(20):7743. doi:10.3390/ijms21207743.
   PubMed Web of Science ®Google Scholar
• Go E-J, Yang H, Chon HJ, Yang D, Ryu W, Kim D-H, Han DK, Kim C, Park W. Combination of irreversible electroporation and sting agonist for effective cancer immunotherapy. Cancers (Basel). 2020;12(11):3123. doi:10.3390/cancers12113123.
   PubMed Web of Science ®Google Scholar
• Park HS, Kim YM, Kim S, Lee WS, Kong SJ, Yang H, Kang B, Cheon J, Shin S-J, Kim C, et al. High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer. J. Immunother. Cancer. 2021;9(10):e003353. doi:10.1136/jitc-2021-003353.
   PubMed Web of Science ®Google Scholar
• Shi J, Chen C, Ju R, Wang Q, Li J, Guo L, Ye C, Zhang D. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy. J. Immunother. Cancer. 2019;7(1):246. doi:10.1186/s40425-019-0725-7.
   PubMed Web of Science ®Google Scholar
• Meininger D, Zalameda L, Liu Y, Stepan LP, Borges L, McCarter JD, Sutherland CL. Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors. Biochim. Biophys. Acta. 2011;1814(12):1947–1954. doi:10.1016/j.bbapap.2011.07.023.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kang SA, Mukherjee T, Bale S, Crane BR, Begley TP, Ealick SE. Crystal structure and mechanism of tryptophan 2,3-dioxygenase, a heme enzyme involved in tryptophan catabolism and in quinolinate biosynthesis. Biochemistry. 2007;46(1):145–155. doi:10.1021/bi0620095.
   PubMed Web of Science ®Google Scholar
• Rohrig UF, Majjigapu SR, Vogel P, Zoete V, Michielin O. Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. J. Med. Chem. 2015;58(24):9421–9437. doi:10.1021/acs.jmedchem.5b00326.
   PubMed Web of Science ®Google Scholar
• Zhang G, Xing J, Wang Y, Wang L, Ye Y, Lu D, Zhao J, Luo X, Zheng M, Yan S. Discovery of Novel Inhibitors of Indoleamine 2,3-Dioxygenase 1 Through Structure-Based Virtual Screening. Front. Pharmacol 2018:9:277. doi:10.3389/fphar.2018.00277.
   Web of Science ®Google Scholar
• Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van Den Eynde BJ. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003;9(10):1269–1274. doi:10.1038/nm934.
   PubMed Web of Science ®Google Scholar
• Balog A, Lin TA, Maley D, Gullo-Brown J, Kandoussi EH, Zeng J, Hunt JT. Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor. Mol. Cancer Ther. 2021;20(3):467–476. doi:10.1158/1535-7163.MCT-20-0251.
   PubMed Web of Science ®Google Scholar
• Schramme F, Crosignani S, Frederix K, Hoffmann D, Pilotte L, Stroobant V, Preillon J, Driessens G, Van Den Eynde BJ. Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors. Cancer Immunol. Res. 2020;8(1):32–45. doi:10.1158/2326-6066.CIR-19-0041.
   PubMed Web of Science ®Google Scholar
• Jonescheit H, Oberg HH, Gonnermann D, Hermes M, Sulaj V, Peters C, Kabelitz D, Wesch D. Influence of Indoleamine-2,3-Dioxygenase and Its Metabolite Kynurenine on gammadelta T Cell Cytotoxicity against Ductal Pancreatic Adenocarcinoma Cells. Cells. 2020;9(5):1140. doi:10.3390/cells9051140.
   PubMed Web of Science ®Google Scholar